...So what is Precision measuring up to these four key attributes? One, manufacturing. We're able to consistently manufacture high quality GMP CAR T cells at scale. Secondly, our drug product consistently comprises at least 50% naive and central memory T cell phenotypes. Third, as we reported last year, while early, we have seen a very encouraging safety profile with no graft versus host disease, no severe CRS or neurotoxicity, and importantly, no infections due to lymphodepletion, and lastly, we saw encouraging early evidence of clinical activity, even at very low dose levels. It has been a big year for Precision. We transition from a preclinical into a clinical development stage company. And just about a year and a half, we have launched three clinical trials. And part of the reason that we were able to do so is that there is a lot of similarity across the three therapeutics that we have put into the clinic, namely the ARCUS enzyme we use is the same and the manufacturing process is similar....
